Leadership & Pay ·
Verastem names Michael Bailey CEO effective Jan 1, 2027 as Daniel Paterson retires
VSTMVerastem, Inc.
Verastem announced that Daniel Paterson will retire as President and Chief Executive Officer on January 1, 2027. Michael Bailey has been appointed to succeed him as CEO and will continue serving as a Class II director. Mr. Paterson will remain on the Board of Directors as a Class III director and serve in an advisory capacity. The filing also disclosed preliminary Q3 2026 net product revenue estimated at $23.9 million to $24.1 million, compared to $11.2 million in the prior year period. Additionally, Verastem terminated its at-the-market equity offering prospectus with Cantor Fitzgerald and reported that the FDA accepted a New Drug Application for VS-7375 with priority review designation. Verastem is a biopharmaceutical company developing and commercializing medicines for RAS/MAPK pathway-driven cancers.